Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review.
about
Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophreniaFactors associated with medication adherence among patients with schizophrenia in Mekelle, Northern EthiopiaEffective Strategies for Nurses Empowering Clients With Schizophrenia: Medication Use as a Tool in Recovery.Adherence and rehospitalizations in patients with schizophrenia: evidence from Japanese claims data.Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medicationDrug Utilization of Japanese Patients Diagnosed with Schizophrenia: An Administrative Database Analysis.Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophreniaMoney for medication: a randomized controlled study on the effectiveness of financial incentives to improve medication adherence in patients with psychotic disorders.Measuring adherence to medication in schizophrenia: the relationship between attitudes toward drug therapy and plasma levels of new-generation antipsychotics.Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in JapanRelationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study.Prevalence and predictors of sub-optimal medication adherence among patients with severe mental illnesses in a tertiary psychiatric facility in Maiduguri, North-eastern Nigeria.Maintaining Adherence Programme: evaluation of an innovative service modelTreatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptomsEfficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority StudyPolygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach.Factors Associated with Adherence to the HEDIS Quality Measure in Medicaid Patients with Schizophrenia.Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional studyPatient advocacy: Japanese psychiatric nurses recognizing necessity for intervention.Depot-medication compliance for patients with psychotic disorders: the importance of illness insight and treatment motivation.The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis.Experiences of antipsychotic use in patients with early psychosis: a two-year follow-up studyThe Pharmacokinetics of Second-Generation Long-Acting Injectable Antipsychotics: Limitations of Monograph Values.Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia.Cariprazine: A Review in Schizophrenia.Medication adherence in patients with schizophrenia.Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study.Cannabis use and adherence to antipsychotic medication: a systematic review and meta-analysis.Exploratory analysis of the French version of the beliefs about medicines questionnaire in patients with severe mental disorders: Factorial structure and reliability in specific populations of schizophrenic, bipolar and depressive patients.Schizophrenia: Impact of psychopathology, faith healers and psycho-education on adherence to medications.Risperidone long-acting injection and 1-year rehospitalization rate of schizophrenia patients: A retrospective cohort study.Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations.Clinical characteristics of individuals with schizophrenia and hallucinogen persisting perception disorder: a preliminary investigation.The effectiveness of a nursing discharge programme to improve medication adherence and patient satisfaction in the psychiatric intensive care unit.Psychotropic medication non-adherence and associated factors among adult patients with major psychiatric disorders: a protocol for a systematic review.Once-monthly injection of paliperidone palmitate in patients with recently diagnosed and chronic schizophrenia: a post-hoc comparison of efficacy and safety.Exploring service users', carers' and professionals' perspectives and experiences of current antipsychotic prescribing: A qualitative study.GPs' views and perspectives on patient non-adherence to treatment in primary care prior to suicide.Treatment response and tolerability with once-monthly paliperidone palmitate initiated shortly after hospital admission in patients with schizophrenia.No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia.
P2860
Q26745792-16CAF68F-AA37-462B-9E79-31F6A078C614Q28545127-6F8332EC-7300-4E51-BA15-CFAA89451AC3Q30276915-F5302C8C-FA8C-41F4-B6F9-5FCD76D31A51Q30937746-50D215B4-DCE5-4633-922A-0055D1651479Q33595935-AC727CEA-1D1F-47DC-A511-85316B3BC4D8Q33650097-07D7224D-F267-4F2E-B3D9-FAF196969B70Q33759300-A3A1D37B-E6BB-47C3-BB8D-1713FDE38F97Q34650576-CED54FA3-EC78-48FD-BBED-E476B7B8753DQ35224289-9859781E-3A15-41F6-A737-95EC28C885A9Q35659829-6D726867-5CE7-4ED9-AAF2-5DB41B953E24Q35736374-BC41EF61-1D43-4238-981A-31CCF31A92EFQ36042870-AE4D5345-9753-4DC8-88B0-D197471D49C4Q36623532-5F056931-4061-4091-8799-F93F1E9AA460Q36992316-9E6E2353-0F8F-4B04-AADE-989F2EC5F85CQ37137799-68E5AAC0-A2CB-4500-8D52-D9EE3EDA6D51Q37170587-C6C48B66-BE0F-4547-AF36-32A3F2AC1A9EQ37441407-536AC555-910E-466C-A2A4-FA2CC71D9170Q37547469-12633B11-F3AF-40A9-AC11-A513CF85A417Q38253168-D115515E-0E20-49AF-AACB-6A6BE753AD3FQ38287203-DA1BD1A9-90A8-4DAD-A961-A433D29C64BBQ38610490-FCAB9392-DE72-46A7-8771-D38741C7E94EQ38613680-896A02BE-E6D9-4F8A-8E5A-00BF8A49A8C3Q38639268-C10F97F1-88E6-4679-8196-1D834EBCA1C4Q38697025-0797C13D-6677-445B-B2C0-F6ADC324AA11Q38754971-17233C9B-CE32-442F-A6F8-8AD81E5D03BDQ38808583-2BE1F956-3DB3-4B36-BE7C-1CD28198977CQ38997108-371B8F22-CD47-4FCA-97A3-E5E3048EC875Q39126835-B4205249-37C0-4FE4-8788-20C40851C653Q40309621-820ED987-4BE3-4257-B3EB-313AF2BDBE72Q40488575-262E264D-D20D-490F-BCCD-2B26568276E4Q41204400-5B21DB6D-76F0-4929-A087-B5B12EA3D90AQ42659528-03214846-B907-4F45-A0BF-BC6C00C3DF32Q44697721-732A838D-04F4-4245-B564-087FCD08BF98Q47431234-3A516305-251D-4EEF-8329-0786A3D10A95Q47555919-7B6A5F1E-74C5-457D-8E46-D4604C30599EQ47574118-6DC82621-6352-480C-9C92-8F36B9032ACFQ47577273-810CAE22-60EC-499E-B22A-E32976A41F6BQ47688187-32142584-E9B6-4541-9DE4-A95A982AD4D5Q47699839-C0173EC7-21C3-4A04-8116-5A5E823CABF8Q47785459-5B98871C-9EB4-4E20-9560-4120513BAF27
P2860
Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Medication adherence in schizo ...... systematic literature review.
@en
Medication adherence in schizo ...... systematic literature review.
@nl
type
label
Medication adherence in schizo ...... systematic literature review.
@en
Medication adherence in schizo ...... systematic literature review.
@nl
prefLabel
Medication adherence in schizo ...... systematic literature review.
@en
Medication adherence in schizo ...... systematic literature review.
@nl
P2093
P2860
P356
P1476
Medication adherence in schizo ...... systematic literature review.
@en
P2093
Kavi J Littlewood
Kyoko Higashi
Marc De Hert
Ola Granström
Teresa Diez
P2860
P304
P356
10.1177/2045125312474019
P50
P577
2013-08-01T00:00:00Z